InsidersTradesSigma
HLB제약: directors' dealings · South Korea · DART (FSS)
DART:hlb-cbc202KR·DART (FSS)Mcap 451.0Bn€Healthcare
Explore the full directors' dealings record of HLB제약, a listed equity based in South Korea. Shares are quoted on KR KR, under the supervision of DART (FSS). Operating in the Healthcare sector, HLB제약 has recorded 2 insider filings. Market capitalisation: €451bn. The latest transaction was filed on 23 April 2026 — Other. Among the most active insiders: HLB생명과학. Every trade is openly available.
2
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
Financial data
FY ended December 2025 · cache
13750.00 €
Analyst consensus
Income statement
Revenue205.58 Bn€
Gross profit106.50 Bn€52% margin
Net income4.57 Bn€-53.4% margin
Valuation
Beta1.83
Balance sheet & cash
Market cap450.98 Bn€
Total debt20.68 Bn€
Free Cash Flow−6.64 Bn€
Debt / Equity17%
Profitability & ownership
ROE-39.8%
ROA-11.7%
% insiders20.9%
% institutions0.5%
Last declaration on 23 April 2026
Declarations0 total
No declarations found
0 of 0 declarations